Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vistakon Pharmaceuticals
• Treatments: Ophthalmic Solutions

Criteria

Inclusion Criteria:

• history of ocular allergies and a positive skin test reaction to cat hair,

• cat dander, grasses, ragweed, and/or trees within the past 24 months;

• calculated best-corrected visual acuity of 0.6 logMar or better in each eye; - positive bilateral conjunctival allergy challenge reaction

Exclusion Criteria:

• narrow angle glaucoma,

• clinically significant blepharitis, follicular conjunctivitis, iritis

• pterygium or diagnosis of dry eye

• ocular surgical intervention within 3 months

• history of refractive surgery within 6 months

• known history of retinal detachment, diabetic retinopathy, or progressive retinal disease

• presence of active ocular infection positive history of an ocular herpetic infection

• preauricular lymphadenopath manifest signs or symptoms of clinically active allergic conjunctivitis